Exploring Best Practices for Diagnosis and Management of Adult-Onset Stills Disease

To participate in this activity, please:

Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medication approved in the United States for the disease. Case studies are utilized to share the faculty’s experience in diagnosis and treatment, so as to facilitate integration into clinical practice.

This program is also available as a podcast.  You may download it here: https://anchor.fm/aosd-podcast

Course Credit:

1.25 AMA PRA Category 1 CreditsTM
1.25 ANCC Contact Hours

Dates:

Opens: 2021-06-30
Closes: 2022-06-30

Target Audience:

This activity is intended for rheumatologists, rheumatology advanced practice providers, dermatologists, primary care physicians, and other clinicians involved in the care of patients with adult-onset Still’s disease.

This activity is supported by an independent educational grant from Novartis Pharmaceutical Corporation.

    Presenting Faculty

  • Petros Efthimiou, MD, FACR

    New York Rheumatology Care, PC
    New York, New York
    Clinical Professor of Medicine
    Ross University School of Medicine
    Miramar, Florida

  • Olga Petryna, MD, FACR

    Clinical Assistant Professor
    Division of Rheumatology
    NYU Grossman School of Medicine
    New York, New York

Learning Objectives

  • Describe the optimal pathway of diagnosis for a patient presenting with possible adult-onset Still’s disease (AOSD), using resources available in the average clinical setting.
  • Develop a personalized treatment strategy for AOSD, taking into consideration a patient’s subtype and risk assessment for systemic complications.
  • Describe the mechanism of action, safety, and efficacy of new and emerging biologic treatments for AOSD.
  • Consider patient HRQoL as part of an AOSD treatment monitoring protocol.

Faculty Disclosures

Petros Efthimiou, MD, FACR

Consultant: AbbVie, Kiniksa, Novartis

Speaker: AbbVie, Amgen, Horizon, Kiniksa, Mallinckrodt, Novartis, Pfizer, Sanofi, UCB


Olga Petryna, MD, FACR

No relationships to disclose.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.25 contact hours may be earned for successful completion of this activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.